|
|
||||||||
Reviews |
a Zurich Lung Transplantation Group, Division of Thoracic Surgery, University Hospital, Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland
b Zurich Lung Transplantation Group, Division of Pulmonary Medicine, University Hospital, Zurich, Zurich, Switzerland
Received 7 August 2008; received in revised form 3 February 2009; accepted 20 February 2009.
* Corresponding author. Address: Medical/Scientific Expert, Novartis Pharma AG, Basel and Visiting Physician, Division of Thoracic Surgery, University Hospital Zurich, Raemistrasse 100, CH - 8091 Zurich, Switzerland. Tel.: +41 44 255 88 02; fax: +41 44 255 88 05. (Email: stephankorom{at}hotmail.com).
The coming of age of lung transplantation is accompanied by an immunosuppressive armamentarium that has been brought forward from other transplant indications. Widely employed on the basis of few small randomized studies, and mostly single-center experience or empirical expert knowledge, anti-rejection therapeutic strategies in pulmonary transplantation have hardly been rigorously evaluated in large-scale prospective international trials. This review compiles the available findings on the use of current immunosuppressants in clinical lung transplantation, accentuating high level-of-evidence study results. Reporting on recent meeting and registry data, and assembling ongoing relevant trials from international databases, this article serves as an update on the state of the art of immunosuppression in lung transplantation.
Key Words: Lung transplantation Immunosuppression State of the art
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |